These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 12541992)

  • 1. New research confirms role of heart disease as a treatment by-product.
    AIDS Alert; 2003 Jan; 18(1):1, 4-6. PubMed ID: 12541992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New HIV guidelines offer adverse effects data.
    AIDS Alert; 2002 Jul; 17(7):89-91. PubMed ID: 12116974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some PIs have greater impact than others on heart disease. Patients on atazanavir had less heart problems.
    AIDS Alert; 2006 Feb; 21(2):17-8. PubMed ID: 16562335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AACTG recommendations for metabolic problems. Guide covers insulin resistance and diabetes.
    AIDS Alert; 2003 Jan; 18(1):6. PubMed ID: 12541993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic complications of HIV infection: translating research findings into clinical practice.
    Currier J
    AIDS Clin Care; 2002 Jan; 14(1):1-2, 8. PubMed ID: 11802627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing issues related to antiretroviral therapy.
    Lesho EP; Gey DC
    Am Fam Physician; 2003 Aug; 68(4):675-86. PubMed ID: 12952384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
    Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
    AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the aetiology of dyslipidaemia and hyperlipidaemia in patients with HIV.
    Moyle G
    Int J STD AIDS; 2005 Oct; 16 Suppl 1():14-20; discussion 20-2, 41-3. PubMed ID: 16238827
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretroviral drugs and the risk of myocardial infarction.
    Pollack TM; Rind DM
    N Engl J Med; 2007 Aug; 357(7):716; author reply 716-7. PubMed ID: 17703531
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiretroviral drugs and the risk of myocardial infarction.
    Kaplan RC; Tien PC; Lazar J
    N Engl J Med; 2007 Aug; 357(7):715; author reply 716-7. PubMed ID: 17699825
    [No Abstract]   [Full Text] [Related]  

  • 12. Sex differences in adverse reactions to antiretroviral drugs.
    Ofotokun I; Pomeroy C
    Top HIV Med; 2003; 11(2):55-9. PubMed ID: 12717043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side effects. The usual suspects.
    TreatmentUpdate; 2002 Nov; 14(8):1-2. PubMed ID: 12501819
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.
    Barreiro P; García-Benayas T; Soriano V; Gallant J
    AIDS Rev; 2002; 4(4):233-41. PubMed ID: 12555697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease inhibitors: emerging research explores possible link with heart disease. Experts say PI therapy remains essential for most.
    AIDS Alert; 2008 Jun; 23(6):61-3. PubMed ID: 18724480
    [No Abstract]   [Full Text] [Related]  

  • 17. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
    Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D;
    AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiretroviral treatment for HIV and adipose tissue].
    Caron M; Bastard JP; Auclair M; Vigouroux C; Capeau J
    Journ Annu Diabetol Hotel Dieu; 2003; ():147-58. PubMed ID: 12868307
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiretroviral drugs and the risk of myocardial infarction.
    Zangerle R; Sarcletti M
    N Engl J Med; 2007 Aug; 357(7):715-6; author reply 716-7. PubMed ID: 17703532
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.